Back to Search
THEODORE SOUTHGATE, MD
MD
Cardiovascular Disease Physician
NPI: 1730156217IndividualAccepts Medicare
Specialties, Licenses & Credentials
Cardiovascular Disease PhysicianPrimary
Internal Medicine — Cardiovascular Disease
Code: 207RC0000X
25MA05005700(NJ)
CMS Specialties
PrimaryGENERAL SURGERY
Education
UNIVERSITY OF MICHIGAN MEDICAL SCHOOL
Class of 1980
Research & Publications (20)
Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4).
PMID 19221742·Cancer Immunol Immunother·2009
8-other
Hypoxia response element-driven cytosine deaminase/5-fluorocytosine gene therapy system: a highly effective approach to overcome the dynamics of tumour hypoxia and enhance the radiosensitivity of prostate cancer cells in vitro.
PMID 19051213·J Gene Med·2009
8-other
Gene transfer into neural cells in vitro using adenoviral vectors.
PMID 18972378·Curr Protoc Neurosci·2008
7-preclinical
O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy.
PMID 18245773·Br Med Bull·2008
6-review
Hypoxia-targeted over-expression of carboxylesterase as a means of increasing tumour sensitivity to irinotecan (CPT-11).
PMID 17397102·J Gene Med·2007
7-preclinical
E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells.
PMID 17507657·Mol Biol Cell·2007
7-preclinical
Diffusible VP22-E2 protein kills bystander cells and offers a route for cervical cancer gene therapy.
PMID 16454648·Hum Gene Ther·2006
7-preclinical
Dual agent chemoprotection by retroviral co-expression of either MDR1 or MRP1 with the P140K mutant of O6-methylguanine-DNA-methyl transferase.
PMID 16733832·J Gene Med·2006
7-preclinical
Radioprotective gene therapy through retroviral expression of manganese superoxide dismutase.
PMID 16506247·J Gene Med·2006
7-preclinical
Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivo.
PMID 16397508·Gene Ther·2006
7-preclinical
The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine.
PMID 16075413·J Gene Med·2006
7-preclinical
Genetic manipulation of drug sensitivity in haematopoietic cells.
PMID 15387894·Expert Rev Mol Med·2004
6-review
Molecular therapy in a model neuroendocrine disease: developing clinical gene therapy for pituitary tumours.
PMID 11167123·Trends Endocrinol Metab·2001
6-review
Gene transfer into neural cells in vitro using adenoviral vectors.
PMID 18428483·Curr Protoc Neurosci·2001
7-preclinical
Long-term transgene expression within the anterior pituitary gland in situ: impact on circulating hormone levels, cellular and antibody-mediated immune responses.
PMID 11145611·Endocrinology·2001
7-preclinical
Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomas.
PMID 10720079·J Clin Endocrinol Metab·2000
7-preclinical
Central nervous system toxicity of two adenoviral vectors encoding variants of the herpes simplex virus type 1 thymidine kinase: reduced cytotoxicity of a truncated HSV1-TK.
PMID 10800091·Gene Ther·2000
7-preclinical
Adenoviruses encoding HPRT correct the biochemical abnormalities fully only in HPRT-deficient human cell lines: importance of species differences.
PMID 11783514·Adv Exp Med Biol·2000
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 201 LYONS AVE
NEWARK, NJ 07112 - Phone
- (973) 926-7749
Quick Facts
- NPI
- 1730156217
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 46
- Publications
- 20
Are you this provider?
Claim Your Profile